Author:
Toja-Camba Francisco José,Vidal Gonzalo Hermelo,Vidal-Millares María,Durán-Maseda María José,Rial-Pérez Alicia,Maroñas Olalla,Carracedo Angel,Gestal Ana Estany,Cajade-Pascual Francisco,Zarra-Ferro Irene,Fernández-Ferreiro Anxo,Mondelo-García Cristina
Funder
Instituto de Salud Carlos III
Sociedad Española de Farmacia Hospitalaria
Xunta de Galicia
Axencia Galega de Innovación
Reference31 articles.
1. The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release;Aihara;Brain Res.,2004
2. High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme;Apellániz-Ruiz;Pharm. J.,2015
3. Aripiprazole, a novel atypical antipsychotic drug;Argo;Pharmacotherapy,2004
4. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 polymorphisms on pharmacokinetics and safety of aripiprazole in healthy volunteers;Belmonte;Basic Clin. Pharmacol. Toxicol.,2018
5. Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics;Beunk;Eur. J. Hum. Genet.,2023